H 
Hebei Changshan Biochemical Pharmaceutical Co 300255.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
19.58
-0.91%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥875.1m
FY2016FY2025
Net income
−CN¥357.9m
FY2016FY2025
Free cash flow
−CN¥67.7m
FY2016FY2025
Shareholders' equity
CN¥1.20bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥875.1m | CN¥1.03bn | CN¥1.41bn | CN¥2.34bn | CN¥2.97bn | CN¥2.36bn | CN¥2.07bn | CN¥1.65bn | CN¥1.42bn | CN¥1.12bn |
| Research and development | CN¥34.1m | CN¥47.2m | CN¥158.8m | CN¥145.0m | CN¥150.6m | CN¥127.5m | CN¥135.9m | CN¥98.9m | CN¥75.9m | CN¥55.1m |
| Operating income | −CN¥92.8m | −CN¥178.8m | −CN¥1.14bn | CN¥20.5m | CN¥262.0m | CN¥309.2m | CN¥262.4m | CN¥172.7m | CN¥260.6m | CN¥225.6m |
| Net income | −CN¥357.9m | −CN¥249.5m | −CN¥1.24bn | CN¥17.5m | CN¥233.6m | CN¥252.8m | CN¥225.3m | CN¥140.0m | CN¥196.9m | CN¥175.5m |
| Diluted earnings per share | -0.39 | -0.27 | -1.38 | 0.02 | 0.25 | 0.26 | 0.23 | 0.16 | 0.22 | 0.23 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥4.35bn | CN¥4.52bn | CN¥4.60bn | CN¥6.04bn | CN¥5.19bn | CN¥4.57bn | CN¥3.94bn | CN¥3.84bn | CN¥3.53bn | CN¥3.13bn |
| Cash and short-term investments | — | CN¥236.4m | CN¥230.9m | CN¥797.8m | CN¥543.2m | CN¥481.0m | CN¥563.3m | CN¥1.02bn | CN¥1.05bn | CN¥1.04bn |
| Total liabilities | CN¥3.18bn | CN¥2.99bn | CN¥2.80bn | CN¥2.98bn | CN¥2.12bn | CN¥1.72bn | CN¥1.22bn | CN¥1.32bn | CN¥1.09bn | CN¥842.6m |
| Debt | CN¥584.3m | CN¥1.55bn | CN¥1.74bn | CN¥2.10bn | CN¥1.56bn | CN¥1.29bn | CN¥617.6m | CN¥953.5m | CN¥732.0m | CN¥608.6m |
| Shareholders' equity | CN¥1.20bn | CN¥1.56bn | CN¥1.81bn | CN¥3.06bn | CN¥3.07bn | CN¥2.85bn | CN¥2.71bn | CN¥2.51bn | CN¥2.37bn | CN¥2.23bn |
| Shares outstanding | 919m | 923m | 901m | 919m | 919m | 956m | 980m | 892m | 904m | 773m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥55.7m | CN¥56.2m | CN¥33.7m | CN¥3.1m | CN¥2.9m | −CN¥183.6m | −CN¥58.1m | CN¥292.8m | CN¥162.3m | CN¥172.0m |
| Capital spending | −CN¥123.4m | −CN¥239.6m | −CN¥239.3m | −CN¥431.2m | −CN¥308.1m | −CN¥199.8m | −CN¥163.4m | −CN¥234.8m | −CN¥158.3m | −CN¥96.5m |
| Free cash flow | −CN¥67.7m | −CN¥183.4m | −CN¥205.6m | −CN¥428.1m | −CN¥305.2m | −CN¥383.4m | −CN¥221.5m | CN¥58.0m | CN¥4.0m | CN¥75.4m |
| Dividends paid | −CN¥118.7m | −CN¥119.9m | −CN¥107.7m | −CN¥124.0m | −CN¥61.9m | −CN¥12.2m | −CN¥26.2m | −CN¥61.4m | −CN¥47.7m | −CN¥51.5m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥219.7m | CN¥256.1m | CN¥193.9m | CN¥189.6m | CN¥232.9m | CN¥258.7m | CN¥246.8m | CN¥216.2m |
| Operating income | CN¥1.2m | CN¥28.1m | −CN¥80.5m | −CN¥1.4m | −CN¥20.1m | CN¥23.4m | −CN¥173.3m | CN¥6.6m |
| Net income | −CN¥22.6m | CN¥5.9m | −CN¥313.1m | −CN¥15.7m | −CN¥32.9m | CN¥3.8m | −CN¥256.8m | CN¥54.2m |
| Diluted earnings per share | -0.02 | 0.01 | -0.34 | -0.02 | -0.04 | 0.00 | -0.28 | 0.06 |
| Cash from operations | — | — | — | −CN¥30.0m | CN¥70.0m | CN¥102.0m | −CN¥94.0m | −CN¥42.0m |
| Capital spending | −CN¥37.0m | −CN¥29.0m | −CN¥51.0m | −CN¥24.0m | −CN¥18.0m | −CN¥28.0m | −CN¥121.0m | −CN¥24.0m |
| Free cash flow | — | — | — | −CN¥54.0m | CN¥52.0m | CN¥74.0m | −CN¥215.0m | −CN¥66.0m |
| Total assets | CN¥4.49bn | CN¥4.44bn | CN¥4.35bn | CN¥4.66bn | CN¥4.54bn | CN¥4.55bn | CN¥4.52bn | CN¥4.69bn |
| Cash and short-term investments | — | — | — | CN¥247.9m | CN¥217.8m | CN¥280.8m | CN¥236.4m | CN¥314.2m |
| Debt | CN¥814.7m | CN¥775.9m | CN¥584.3m | CN¥1.93bn | CN¥1.56bn | CN¥1.52bn | CN¥1.55bn | CN¥1.64bn |
| Shareholders' equity | CN¥1.19bn | CN¥1.21bn | CN¥1.20bn | CN¥1.52bn | CN¥1.53bn | CN¥1.57bn | CN¥1.56bn | CN¥1.82bn |
Financial ratios
Data as of 21 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | -10.6% | -17.3% | -81.2% | 0.9% | 8.8% | 13.1% |
| Net margin | -40.9% | -24.2% | -87.9% | 0.7% | 7.9% | 10.7% |
| Return on equity | -29.7% | -16.0% | -68.5% | 0.6% | 7.6% | 8.9% |
| Return on assets | -8.2% | -5.5% | -27.0% | 0.3% | 4.5% | 5.5% |
| Free cash flow yield | 0.8% | 1.3% | 1.3% | 2.0% | 1.4% | 0.1% |
| Revenue growth | -15.1% | -26.9% | -39.6% | -21.3% | 25.6% | 14.1% |
| Earnings growth | 43.5% | -79.9% | -7181.5% | -92.5% | -7.6% | 12.2% |
| Current ratio | 0.69x | 0.91x | 1.18x | 2.18x | 1.97x | 2.12x |
| Debt to equity | 0.49x | 0.99x | 0.96x | 0.69x | 0.51x | 0.45x |
| Equity ratio | 27.7% | 34.5% | 39.4% | 50.7% | 59.1% | 62.3% |
| Interest coverage | -0.96x | -1.70x | -11.50x | 0.20x | 3.77x | 4.87x |
| R&D as a share of sales | 3.9% | 4.6% | 11.3% | 6.2% | 5.1% | 5.4% |
| Buybacks as a share of market value | 0.5% | -2.5% | 2.0% | 0.0% | 3.8% | 2.5% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -27.9% | -18.0% | -0.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | -14.2% | -24.7% | -7.5% | 1.5% |
| Net margin | -31.9% | -32.4% | -12.2% | -2.5% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | -159.5 | -74.0 | -9.4 | 287.6 | 32.0 | 23.4 | 23.7 | 26.1 | 29.1 | 34.8 |
| Price to sales | 65.2 | 17.9 | 8.3 | 2.2 | 2.5 | 2.5 | 2.6 | 2.2 | 4.0 | 5.5 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years. Last went ex-dividend on 27 Jun 2023.
| FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.005 | 0.026 | 0.013 | 0.028 | 0.02 | 0.015 | 0.029 | 0.019 |
- 9-for-5 split · 20 Apr 2016
- 5-for-2 split · 30 Apr 2015
- 17-for-10 split · 10 Jul 2012
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.